Freddy Shanner, MD

Nephrologist -Membership:@SLANH_ @ASNkidney @ISNKidneycare @ERAKidney @AST_info @Glomcon I can do all things through Christ which strengtheneth me
Phil 4:13🇵🇪

[Freddy Shanner, MD @FreddyShanner]

#VII Congreso Chileno de trasplante 2021 - 🔉🔊🎧

[FDA Drug Information @FDA_Drug_Info]

The FDA has approved new warning labels for the OTC weight loss drug alli (orlistat) 60 mg to alert users of rare but serious risks of kidney stones and kidney injury. https://t.co/HodTstWxeN

[S.E.N. Nefrología @SENefrologia]

🔴 ¡No te lo pierdas! | 🔥 WEBINAR: Lo más destacado del 63º Congreso de la ERA #ERA2026 @senjoven
📅 Lunes, 29 de junio 2026 🕓 16h CEST
✍️ Inscripciones: https://t.co/SHE98wBgyD
🎙️ Moderado por Iñigo Yáñez Mendía @OSIEECruces
🙌 Gracias a @NovoNordiskES @CSL_spain @STADA

[Hans-Joachim Anders @hjanders_hans]

Just released the Impact Factors of some #kidney journals. @ERAkidney @ISNkidneycare @asnpublications @NatRevNeph

[Saavedra @FernandaSV94]

La pregunta ya no es si la diálisis peritoneal funciona en la LRA.
La evidencia dice que sí. La verdadera pregunta es: ¿por qué seguimos utilizándola tan poco?

Ventajas:
-Mayor estabilidad hemodinámica
-No requiere acceso vascular ni anticoagulación sistémica
-Menor riesgo de bacteriemia asociada a catéter
-Útil en estados de hipercoagulabilidad y entornos con recursos limitados

[Brendon Neuen @brendonneuen]

In patients with GN (n=903) in FIND-CKD, treatment with finerenone:

- Slowed the rate of GFR decline
- Reduced UACR by 42%
- Lowered the risk of kidney failure or 40% decline in eGFR by 26%

Results consistent regardless of GN subtype & SGLT2i use #ERA26

https://t.co/tem1zQ5GN5

[Freddy Shanner, MD @FreddyShanner]

@brendonneuen @HDiniz_ Excellent and amazing paper 📝📝

[Freddy Shanner, MD @FreddyShanner]

@DraNefrona Interesante info 😎😎

[Brendon Neuen @brendonneuen]

Primary results of the FIND CKD trial will be presented on June 5, 11:15 BST in the late breaking clinical trial session at @ERAkidney #ERA26

[Gopambuj Singh Rathod @IamGopambuj]

Membranous nephropathy is no longer just “primary vs secondary” disease — it is now an ANTIGEN-SPECIFIC podocytopathy.

🔬 Newer antigens are redefining diagnosis & prognosis:
▪️ NELL1 → malignancy/drug-associated MN
▪️ EXT1/EXT2 & NCAM1 → lupus/autoimmune MN
▪️ SEMA3B → pediatric MN
▪️ FAT1 → post-HSCT MN
▪️ CNTN1 → neuropathy-associated MN
▪️ PCDH7 → indolent MN phenotype

⚡ Emerging concept: Dual-antigen MN
(NELL1+PLA2R, NCAM1+EXT1/2 etc.) suggesting complex autoimmune evolution.

🧪 Mass spectrometry-based antigen mapping is becoming the future gold standard for PLA2R-negative MN.
#GSR #BuddingNephros #MembranousNephropathy #RenalPathology #NephTwitter #MedTwitter

[Mayo Clinic Nephrology @MayoClinicNeph]

Effects of Hemodiafiltration Versus Hemodialysis on Uremic Toxins, Inflammatory Markers, Anemia, and Nutritional Parameters: A Systematic Review and Meta-Analysis

@wisit661

https://t.co/Et1CB5XCno

[Int Society of Nephrology @ISNkidneycare]

📖 This weekend don't miss our @KIReports #ISNFridaySelection: Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation https://t.co/pL3Wn7zd1i

Grow professionally with the ISN. Access high-impact scientific and clinical research through our journals. Join/renew your ISN membership ➡️ https://t.co/Bw8FJmobhb

#ThisIsISN – Advancing kidney health worldwide. Together.

[Freddy Shanner, MD @FreddyShanner]

@MarieTherese998 @fouadchebib @MayoClinicNeph Excellent 👏👏

[Freddy Shanner, MD @FreddyShanner]

@n0r0zha Blessings pretty woman 😊😊

[Freddy Shanner, MD @FreddyShanner]

@HaddiyaIntissar Blessings

[NEJM @NEJM]

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://t.co/4BWhSd0ZCC

[Freddy Shanner, MD @FreddyShanner]

@ENefros @JonathanNefro @anace710 @VelezNephHepato @OcdulioZedrn @RenalZac @IMINmx @SENefrologia @SLANH_

[GlomCon @GlomCon]

We are pleased to announce GlomCon Europe 2026, scheduled for 16-17 April 2026 at the Altis Grand Hotel in Lisbon, Portugal.

Join us for a gathering of clinicians, scientists, and educators from around the world on all things glomerular diseases.

Learn more: https://t.co/EPJAt2a44B

#GlomCon #GlomConEurope2026

[Freddy Shanner, MD @FreddyShanner]

@GlomCon @SaynaNorouzi I love it 😎😎

[Freddy Shanner, MD @FreddyShanner]

@DraNefrona Tu estas en otro nivel y los 😺😺 lo aplauden tbm 😉😉🤝🤝

[Int Society of Nephrology @ISNkidneycare]

📢 The ISN is proud to announce the launch of Kidney International Case Reports (KICR), a new peer-reviewed, open-access journal dedicated to publishing high-quality case reports, focused reviews, and short clinical communications relevant to kidney care.

An official ISN Journal, KICR joins Kidney International®, Kidney International Reports®, and Kidney International Supplements in the society’s expanding portfolio. The journal aims to accelerate clinical learning for the ISN’s global community by sharing diverse experiences and perspectives in kidney care, highlighting:

➡️ Interesting clinical presentations
➡️ Diagnostic challenges or therapeutic dilemmas
➡️ Novel or unique pathology, imaging, or laboratory findings
➡️ Innovative approaches to kidney care, especially from resource-limited settings

🌍 KICR is now accepting submissions. Find out more about the journal and how to submit 👉 https://t.co/RkTCauLRXE